Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHOW TIME: Short-course preoperative chemoradiotherapy with S-1 + irinotecan followed by CAPOX TNT for locally advanced rectal cancer
jRCTs031210461Phase 1Recruiting
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegafur, irinotecan, capecitabine and oxaliplatin in rectal cancer. Primary endpoints: Phase I Study 1: Maximum tolerated dose (MTD) of S-1 and irinotecan, Phase I Study 1: Recommended dose (RD) of S-1 and irinotecan and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
tegafuririnotecancapecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs031210461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210461.